ERBB2 TMD/JMD mutants bind trastuzumab

Stable Identifier
R-HSA-9665696
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

The following ERBB2 TMD/JMD mutants are sensitive to the therapeutic antibody trastuzumab (herceptin):
ERBB2 V659E (Pahuja et al. 2018);
ERBB2 G660D (Pahuja et al. 2018);
ERBB2 G660R (Pahuja et al. 2018);
ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018);
ERBB2 Q709L (Pahuja et al. 2018);

Literature References
PubMed ID Title Journal Year
23220880 Activating HER2 mutations in HER2 gene amplification negative breast cancer

Bose, R, Kavuri, SM, Searleman, AC, Shen, W, Shen, D, Koboldt, DC, Monsey, J, Goel, N, Aronson, AB, Li, S, Ma, CX, Ding, L, Mardis, ER, Ellis, MJ

Cancer Discov 2013
30449325 Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations

Pahuja, KB, Nguyen, TT, Jaiswal, BS, Prabhash, K, Thaker, TM, Senger, K, Chaudhuri, S, Kljavin, NM, Antony, A, Phalke, S, Kumar, P, Mravic, M, Stawiski, EW, Vargas, D, Durinck, S, Gupta, R, Khanna-Gupta, A, Trabucco, SE, Sokol, ES, Hartmaier, RJ, Singh, A, Chougule, A, Trivedi, V, Dutt, A, Patil, V, Joshi, A, Noronha, V, Ziai, J, Banavali, SD, Ramprasad, V, DeGrado, WF, Bueno, R, Jura, N, Seshagiri, S

Cancer Cell 2018
Participants
Participant Of
Normal reaction
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!